CRISPR Therapeutics
CRSP
CRSP
444 hedge funds and large institutions have $3.25B invested in CRISPR Therapeutics in 2021 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 161 increasing their positions, 128 reducing their positions, and 95 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
444
Holders Change
-26
Holders Change %
-5.53%
% of All Funds
6.86%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
76
Increased
161
Reduced
128
Closed
95
Calls
$219M
Puts
$202M
Net Calls
+$17M
Net Calls Change
+$115M
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$114M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$81.7M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$78.8M |
| 4 |
Renaissance Technologies
New York
|
+$43.9M |
| 5 |
AC
Armistice Capital
New York
|
+$38.8M |
Top Sellers
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$74.5M |
| 2 |
O
OrbiMed
New York
|
-$68.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$44.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$28.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$28.4M |
